Treatment of Neurogenic Orthostatic Hypotension with Droxidopa: Results from a Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Induction Design Study

March 9, 2012

Speaker: Horacio Kaufman, MD, FAAN

Friday, April 27, 2012

12:15 p.m. – 12:30 p.m.

Biographical Information:

Dr. Horacio Kaufmann received his medical degree from the National University of Buenos Aires, Argentina. Following his Neurology residency and fellowship training at Mount Sinai School of Medicine in New York Dr. Kaufmann was appointed to the faculty and later held the Aidekman chair in Neurological Research. Currently, Dr. Kaufmann is Professor of Neurology and Professor of Medicine at New York University where he also holds the Axelrod chair in Dysautonomia Research and directs the Dysautonomia Center.

Dr. Kaufmann’s innovative research on the autonomic nervous system has been funded by the National Aeronautics and Space Administration (NASA), the National Institutes of Health (NIH) the Food and Drug Administration (FDA), the Dana Foundation and the Dysautonomia Foundation, Inc.

Dr. Kaufmann reported the first complete autopsy results in pure autonomic failure establishing this disorder as a synucleinopathy related to Parkinson disease. Dr. Kaufmann first reported target organ damage in patients with autonomic failure as a result of nocturnal hypertension. He described the vestibulo–sympathetic reflex in humans, a feed–forward mechanism that helps maintain blood pressure during movement. Last year, Dr. Kaufmann defined the autonomic phenotype of the genetic disease, familial dysautonomia (Riley Day syndrome) as a disorder of the afferent neurons of the baroreflex.  Recently, Dr. Kaufmann was the principal investigator of the largest multinational clinical trials using L–DOPS, a norepinephrine precursor for the treatment of neurogenic orthostatic hypotension.

He is Editor in Chief of Clinical Autonomic Research.

 email to a friend  |   print